EE200100123A - CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon - Google Patents

CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon

Info

Publication number
EE200100123A
EE200100123A EEP200100123A EEP200100123A EE200100123A EE 200100123 A EE200100123 A EE 200100123A EE P200100123 A EEP200100123 A EE P200100123A EE P200100123 A EEP200100123 A EE P200100123A EE 200100123 A EE200100123 A EE 200100123A
Authority
EE
Estonia
Prior art keywords
lymphocytes
population
binding agent
memory effector
effector
Prior art date
Application number
EEP200100123A
Other languages
English (en)
Estonian (et)
Inventor
Magilavy Daniel
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE200100123A publication Critical patent/EE200100123A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EEP200100123A 1998-08-31 1999-08-31 CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon EE200100123A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9845698P 1998-08-31 1998-08-31
PCT/US1999/020026 WO2000012113A2 (en) 1998-08-31 1999-08-31 Method of modulating memory effector t-cells using a cd2-binding agent, and compositions

Publications (1)

Publication Number Publication Date
EE200100123A true EE200100123A (et) 2002-06-17

Family

ID=22269362

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100123A EE200100123A (et) 1998-08-31 1999-08-31 CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon

Country Status (26)

Country Link
US (2) US20020009446A1 (es)
EP (1) EP1109570B1 (es)
JP (1) JP2002523071A (es)
KR (1) KR20010085687A (es)
CN (1) CN100473417C (es)
AT (1) ATE306932T1 (es)
AU (1) AU764020B2 (es)
BR (1) BR9913285A (es)
CA (1) CA2339299C (es)
CZ (1) CZ298238B6 (es)
DE (1) DE69927831T2 (es)
DK (1) DK1109570T3 (es)
EA (1) EA005948B1 (es)
EE (1) EE200100123A (es)
ES (1) ES2252999T3 (es)
HK (2) HK1038186A1 (es)
HU (1) HUP0103563A3 (es)
IL (2) IL141486A0 (es)
IS (1) IS5848A (es)
MX (1) MXPA01002111A (es)
NO (1) NO20010956L (es)
NZ (1) NZ510831A (es)
PL (1) PL346339A1 (es)
TR (1) TR200100607T2 (es)
WO (1) WO2000012113A2 (es)
ZA (1) ZA200101213B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
NZ510831A (en) * 1998-08-31 2002-12-20 Biogen Inc Method of modulating memory effector T-cells and compositions
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1409015A4 (en) * 2001-02-01 2006-04-12 Biogen Idec Inc METHODS OF TREATING OR PREVENTING SKIN DISORDERS USING CD2 BINDING AGENTS
EP1419236A4 (en) * 2001-07-24 2005-08-03 Biogen Idec Inc METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
WO2005000898A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
WO2005035586A1 (ja) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
MXPA06008918A (es) * 2004-02-06 2007-03-07 Astellas Llc Metodos de tratamiento de trastornos de la piel.
US20080020383A1 (en) * 2004-05-04 2008-01-24 Genaissance Pharmaceuticals, Inc. Haplotype Markers And Methods Of Using The Same To Determine Response To Treatment
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
PL2021025T3 (pl) 2006-05-12 2017-04-28 Ith Immune Therapy Holdings Ab Sposób i środki do leczenia nieswoistego zapalenia jelit
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
US8877177B2 (en) 2008-09-10 2014-11-04 Ith Immune Therapy Holdings Ab Chemokine containing apheresis column and methods of use
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2020236797A1 (en) * 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579844A (en) * 1976-05-13 1986-04-01 Johnson & Johnson Topical anti-inflammatory drug therapy
US4738927A (en) * 1982-03-31 1988-04-19 Ajinomoto Co. Inc. Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
JPH0763830B2 (ja) * 1985-11-26 1995-07-12 アスモ株式会社 ダイカスト鋳造金型への離型剤塗布方法
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
PT503648E (pt) * 1991-03-12 2000-10-31 Biogen Inc Dominio do antigenio 3 associado a funcao linfocitica de ligacao as cd2
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
US5511563A (en) * 1991-06-21 1996-04-30 Diamond; Donald A. Apparatus and method for treating rheumatoid and psoriatic arthritis
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DK0786255T3 (da) * 1991-10-07 2002-04-15 Biogen Inc Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
NZ510831A (en) * 1998-08-31 2002-12-20 Biogen Inc Method of modulating memory effector T-cells and compositions
US6337337B1 (en) * 1998-09-03 2002-01-08 Carol J. Buck Methods for treating disorders responsive to DHFR-inhibition
EP1409015A4 (en) * 2001-02-01 2006-04-12 Biogen Idec Inc METHODS OF TREATING OR PREVENTING SKIN DISORDERS USING CD2 BINDING AGENTS
US20030068320A1 (en) * 2001-03-02 2003-04-10 Christine Dingivan Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders

Also Published As

Publication number Publication date
MXPA01002111A (es) 2003-03-27
IL141486A0 (en) 2002-03-10
HUP0103563A3 (en) 2004-04-28
ATE306932T1 (de) 2005-11-15
KR20010085687A (ko) 2001-09-07
EA005948B1 (ru) 2005-08-25
NO20010956L (no) 2001-04-30
TR200100607T2 (tr) 2001-06-21
DE69927831T2 (de) 2006-07-20
DK1109570T3 (da) 2006-03-06
AU764020B2 (en) 2003-08-07
IL141486A (en) 2007-12-03
WO2000012113A3 (en) 2000-06-29
CZ2001725A3 (cs) 2001-08-15
HK1040186A1 (zh) 2002-05-31
BR9913285A (pt) 2001-05-15
ZA200101213B (en) 2002-02-13
EP1109570B1 (en) 2005-10-19
DE69927831D1 (de) 2006-03-02
HUP0103563A2 (hu) 2002-01-28
CA2339299A1 (en) 2000-03-09
NZ510831A (en) 2002-12-20
CN100473417C (zh) 2009-04-01
ES2252999T3 (es) 2006-05-16
CN1315866A (zh) 2001-10-03
IS5848A (is) 2001-02-16
NO20010956D0 (no) 2001-02-26
US20020009446A1 (en) 2002-01-24
WO2000012113A2 (en) 2000-03-09
EP1109570A2 (en) 2001-06-27
US20060233796A1 (en) 2006-10-19
CZ298238B6 (cs) 2007-08-01
EA200100304A1 (ru) 2001-10-22
PL346339A1 (en) 2002-02-11
HK1038186A1 (en) 2002-03-08
JP2002523071A (ja) 2002-07-30
CA2339299C (en) 2009-02-10
AU6024499A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
EE200100123A (et) CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon
EA200100103A1 (ru) Ингибиторы адгезии клеток
BG101717A (en) Inhibitors of microsomal triglyceride transfer protein and method
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
DE69528528D1 (de) Thrombin-inhibitoren
NO982126D0 (no) Polymere br÷nnkomplotteringssammensetninger og hjelpesammensetninger og fremgangsmÕter for anvendelse av disse
BR0112160A (pt) Agentes antiinflamatórios seletivos para glicocorticóides
DK0970095T3 (da) Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase
GR3036364T3 (en) Compositions and methods for treating or preventing inflammatory diseases
ATE214928T1 (de) Thrombininhibitoren
MX9603845A (es) Profarmacos de antagonistas del receptor de morfolino-taquiquinina.
ZA93811B (en) Methods of treating inflammatory dermatoses.
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
DE69500323T2 (de) Antikorrosiver, kathodischer Elektrotauchlack
BR9907788A (pt) Agentes antiinflamatórios seletivos paraglicocorticóides
NO20006600D0 (no) Ikke-peptidylinhibitorer av VLA-4-avhengig cellebinding nyttig for behandling av inflammatoriske, autoimmune og respiratoriske sykdommer
EP0702566A4 (en) INHIBITION OF THE MIGRATION INHIBITION FACTOR IN THE TREATMENT OF DISEASES IN WHICH A CYTOKIN-MEDIATED TOXICITY PLAYS A ROLE
NO20004052L (no) Glukokortikoidselektive antiinflammatoriske midler
DE69628302D1 (de) Milchige reinigungs- und/oder desinfektionsmittelzusammensetzungenfür harte oberflächen.
ES2172536T3 (es) Liberacion y movilizacion de celulas hematopoyeticas.
ES2139957T3 (es) Metodo para la determinacion del estado pretrombotico.
DE69632580D1 (de) Ausgabestufe für Speicheranlage und für Niederspannungsanwendungen
GB9312315D0 (en) Leukocyte adhesion assay
PT1017667E (pt) 2-amino-6-metil-7-acetil-tetralina e composicoes farmaceuticas para a prevencao e para o tratamento terapeutico de patologias inflamatorias e/ou de natureza autoimunitaria
PT1021200E (pt) Metodos e composicoes para o tratamento da artrite reumatoide

Legal Events

Date Code Title Description
HC1A Change of owner name